| Hans-Günter Meyer-Thompson | Hepatitiden
Hepatitis B: European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection
Vemlidy® is the First New Treatment for Chronic Hepatitis B Infection to be Approved in the European Union in Nearly a Decade. (Gilead Sciences, Inc., 11.01.2017)